



AVHEC 2019

Conference Handbook

2nd Australasian Viral Hepatitis Elimination Conference

5 – 6 August 2019

Novotel Sydney Brighton Beach Hotel

 **#AVHEC19**

 **ashm**

Thank you to our Sponsors & Supporters

Major Sponsors and Supporters



Platinum Sponsor

abbvie

Silver Sponsor

Contents

International Keynote Speakers	2
Floor Plans	4
Exhibition Directory	6
Program	8
Poster Listing	18

National Office
Locked Mail Bag 5057
Darlinghurst NSW 1300,
Australia

M 0458 291 166
E conference@ashm.org.au
W www.ashm.org.au

ABN: 48 264 545 457
CFN: 17788

© ASHM 2019 Design and
layout by Steph Yamey

Printed by TTR Print
Management

Conference Environment Policy

ASHM Conference and Events Division implements a waste-reduction policy that addresses:

- Reduce, Reuse, Recycle. This is done before, during and after each conference.
- ASHM Conference & Events Division reduces the number of printed materials by using electronic communication means wherever possible, including the website, email, online registration and abstract submission.
- ASHM Conference & Events Division monitors final delegate numbers for an accurate forecast of catering requirements in order to avoid waste.
- ASHM Conference & Events Division aims to research and prioritise purchasing items and equipment that support the use of recycled materials or can be recycled after use.
- ASHM Conference & Events Division will aim to ensure that recycling bins are available onsite at all events.
- ASHM Conference & Events Division will endeavor to minimise travel through the use of teleconferences instead of face-to-face meetings and holding meetings only when necessary.

ASHM Conference & Events Division encourages all conference stakeholders to consider the environment by suggesting the following: reduction in printing requirements; recycling conference materials; and reusing conference merchandise.

International Speakers



Saeed Hamid

Director, Clinical Trials Unit, Professor & Consultant
Gastroenterologist, Department of Medicine, Pakistan



Sharon Hutchinson

Professor of Epidemiology and Population Health
at Glasgow Caledonian University, Scotland



Giten Khwairakpam

Community and Policy Program Manager at
AMFAR's TREAT Asia program in Bangkok, Thailand



Dee Lee

Director and founder of Inno Community
Development Organisation, China



Su Wang

MD, MPH is the Medical Director of the Center
for Asian Health, United States of America

Conference App

The Conference App supported by MSD is available to download from the Apple app store or Google Play.



The conference app is the best way to stay informed during the conference and free to download. Here's what you can do with the app:

- View the program by time or session, read the abstracts, make notes and let others know what you think about the session by sharing it on Twitter
- Search for speakers, read their bio and see what presentations they are giving
- View a list of all the sponsors and exhibitors and check which booths they are at
- Interact with social media through Twitter and Facebook.
- Build your own agenda
- Send a direct message to that person you have been trying to pin down for a meeting

Wi-Fi Details

Connect to: **AVHEC19**
Password: **AVHEC19**

How do I get the app?

For most attendees, you are able to download and install your mobile app from your Android or Apple App Stores. For your convenience, we are including direct links to your suitable App Store.

Search for 'Events App by EventsAIR' in the Apple App Store or Google Play Store.

How do I login to the app?


Once you have found the app in your App Store:

1. Install the App.
2. The first time you open the app, you will need to enter the event code: AVHEC19
3. To login, enter your primary email address and pin which you would have received in your app instructions email and final registration confirmation email.


You are all set!

If you have any questions visit the conference team located at the Registration desk!

Venue Floor Plan



Exhibition Floor Plan



Exhibition Directory

Staff at the pharmaceutical company trade displays are precluded by law, and by Medicines Australia code from giving information about specific products to non-healthcare professionals.

BOOTH 8



AbbVie is a highly focused, research-driven biopharmaceutical company. We're a company that takes on some of the toughest health challenges. And we do more than just treat diseases – we aim to make a remarkable impact on people's lives.

BOOTH 9



Cepheid is a leading on-demand molecular diagnostics company that is dedicated to improving healthcare by developing fully-integrated systems and accurate yet easy-to-use molecular tests. The company is focusing on applications where rapid and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases and cancer.

BOOTH 3 & 4



Gilead's mission is to advance patient care by developing therapeutics to treat life-threatening diseases. We apply biopharmaceutical science to create medicines to treat conditions including **Haematology/Oncology (ZYDELIG® [idelalisib])**, **HIV (BIKTARVY® [bictegravir/emtricitabine/tenofovir alafenamide])**, **DESCOVY® [emtricitabine/tenofovir alafenamide]**, **GENVOYA® [elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide]**, **STRIBILD® [tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat]**, **EVIPLERA® [tenofovir disoproxil fumarate/emtricitabine/rilpivirine]**, **ATRIPLA® [tenofovir disoproxil fumarate/emtricitabine/efavirenz]**, **TRUVADA® [emtricitabine/tenofovir disoproxil fumarate]**, **EMTRIVA® [emtricitabine]**, **VIREAD® [tenofovir disoproxil fumarate]**, **chronic hepatitis B (VIREAD® [tenofovir disoproxil fumarate])**, **HEPSERA® [adefovir dipivoxil]**, **chronic hepatitis C (EPCLUSA® [sofosbuvir/velpatasvir])**, **HARVONI® [ledipasvir/sofosbuvir]**, **SOVALDI® [sofosbuvir]**, **VOSEVI® [sofosbuvir/velpatasvir/voxilaprevir]**, and **systemic fungal infections (AmBisome® [liposomal amphotericin B])**.

BOOTH 2

Hepatitis Australia and **Hepatitis NSW** form part of the national network of community hepatitis organisations. We work both together and independently to improve the health and wellbeing of people living with viral hepatitis. Hepatitis Australia is the peak community organisation to progress national action on hepatitis B and hepatitis C. Hepatitis NSW is a state-based organisation, and a member organisation of Hepatitis Australia. It provides information, support, referral, advocacy and community engagement/representation for people affected by viral hepatitis. Through collaboration and partnership at all levels, we believe that the quest to eliminate viral hepatitis as a public health concern by 2030 is achievable, but we need to work together!

BOOTH 5

The beauty of the **Fibroscan** is that the basic principle of measurement has not changed, however, the new transportable model FS430 is much smaller recent hardware and software make accuracy easier and faster by eliminating A and E waves. At some time in the next 6 to 9 months there will be dual probe depth software to reduce capsule errors and CAP will measure steatosis in a potentially larger area, we expect that this will only be available on new devices such as the FS 430-Step2 just released.

Program: Monday

MONDAY 5 AUGUST 2019	
8.00	Registration and Arrival Coffee/Tea
9.30 - 11.00	Opening Plenary Room: Endeavour Ballroom Chairs: Joe Doyle & Annabelle Stevens
9.30 - 9.35	Welcome to Country Uncle Chicka Madden
9.35 - 9.40	Government Welcome
9.40 - 9.45	ASHM Welcome Alexis Apostolellis, CEO, ASHM, Sydney, Australia
9.45 - 9.55	Community Welcome
9.55 - 10.00	Committee Welcome Joseph Doyle, Chair, AVHEC Conference Committee
10.00 - 10.30	Global perspective on viral hepatitis elimination, lessons learned and challenges ahead Saeed Hamid, Aga Khan University, Pakistan
10.30 - 11.00	Lessons learned and challenges ahead: Investing in and sustaining the viral hepatitis response globally Margaret Hellard, Burnet Institute, Melbourne, Australia
11.00 - 11.30	Morning Tea and Poster Viewing - Exhibition Area
11.30 - 1.00	Plenary 2: Improving policy, services and practice Room: Endeavour Ballroom Chairs: Gail Matthews & Lisa Carter
11.30 - 11.45	HCV Elimination in New Zealand - how are we tracking? Ed Gane, University of Auckland, and New Zealand Liver Unit, Auckland City Hospital, Auckland, New Zealand
11.45 - 12.00	Hepatitis C diagnosis and treatment: An update from Asia Giten Khwairakpam, amfAR's TREAT Asia, Thailand
12.00 - 12.15	Lifting the invisibility cloak: the role of nurses in the hepatitis C elimination Jacqui Richmond, Burnet Institute, Melbourne, Australia
12.15 - 12.30	Maximising DAA uptake: Tensions between 'lay' and 'expert' knowledges Joanne Bryant, Centre for Social Research In Health UNSW, Sydney, Australia
12.30 - 1.00	Panel Discussion
1.00 - 2.30	Lunch and Poster Viewing - Exhibition Area

MONDAY 5 AUGUST 2019

1.40 - 2.15	Poster Tour 1	1.40 - 2.15	Multimedia Session
	Room: Exhibition Area Chair: Alisa Pedrana		Room: Endeavour Room 1 Chair: Chris Cunningham
1.40 - 1.45	Nothing About Us Without Us: The Role of Peer Educators in HCV Testing and Treatment Uptake Peta Gava, Peer Based Harm Reduction, Western Australia	1.40 - 1.45	How to Treat Hepatitis C - Developing a Video Resource for People Recently Diagnosed With Hepatitis C David Worthington, WA Department of Health, Western Australia
1.45 - 1.50	Hepatitis C Virus Testing, Liver Disease Assessment and Treatment Uptake Among People Who Inject Drugs Pre- and Post-Universal Access to Direct-Acting Antiviral Treatment in Australia: The Liverlife Study Sahar Bajis, The Kirby Institute, UNSW, Sydney, New South Wales	1.45 - 1.55	3 short films, 3 languages: Are you living with hepatitis C? A cure is available Co-design: Enhancing hepatitis C messaging to reach CALD communities Natali Smud, Senior Health Promotion Officer, Multicultural HIV And Hepatitis Service (MHAHS), New South Wales Denise Voros, Cultural Support Program Coordinator, Diversity Programs & Strategy Hub, Sydney Local Health District, New South Wales
1.50 - 1.55	Universal Blood-Borne Virus Screening in Patients With Severe Mental Illness Managed in an Outpatient Clozapine Clinic: Uptake and Prevalence Jake Williams, St George Hospital, New South Wales		
1.55 - 2.00	Collaborative Approach to the Management of Hepatitis C at Numinbah Queensland Correctional Facility Ingrid Francis, Gold Coast University Hospital, Queensland	1.55 - 2.00	Stigma Stories: Using Story Telling Through Media to #stopstigma Isabelle Purcell, Hepatitis Victoria, Victoria
2.00 - 2.05	Australian Rural Primary Care Led Viral Hepatitis Clinic - Outcome Data from 3 Years of Direct Acting Antiviral Agents (DAA's) Anne Balcomb, Prince St Medical Practice, New South Wales	2.00 - 2.05	Digital Storytelling: A Community Tool to End Hepatitis B and C Stigma and Discrimination Winnie Nguyen, Hepatitis Queensland, Queensland
2.05 - 2.10	Hepatitis C Antibody Testing Trend Pre and Post Universal Access to Direct Acting Antivirals in Australia: Segmented Regression of Primary Care Clinic Data Alisa Pedrana, Burnet Institute, Melbourne, Victoria	2.05 - 2.10	You Can't Hep That! Rhondra Lewis, Cairns Sexual Health Service, Queensland
2.10 - 2.15	Community-Based Point-of-Care Testing and Treatment for People Who Inject Drugs and General Population in Myanmar Bridget Draper, Burnet Institute, Victoria	2.10 - 2.15	Platinum C: A Learning Healthcare System Approach to Optimise the Management of Hepatitis C Nada Andric, Hepatitis WA, Western Australia

Program: Monday

MONDAY 5 AUGUST 2019

2.30 - 4.00	Oral Abstracts 1: Cures and Culture: Focus on people who inject drugs Room: Endeavour Room 1 Chairs: Sally Watkinson & Lise Lafferty	2.30 - 4.00	Oral Abstracts 2: Gains and Gaps: The Hepatitis response in CALD and Indigenous populations Room: Endeavour Room 2 Chairs: Jane Davies & Cristina Lu	2.30 - 4.00	Oral Abstracts 3: From Policy to Service Delivery: The hepatitis response insights and innovations Room: Endeavour Room 3 Chairs: Suzanne Shepherd-Law & Avik Majumdar
2.30 - 2.45	The Impact of Community-Based Rapid Point of Care Testing on Enhancing Uptake of Hepatitis C Treatment For People Who Inject Drugs in Needle and Syringe Services Jessica Howell, St Vincent's Hospital Melbourne/ Burnet Institute, Victoria	2.30 - 2.45	Not on Target For Elimination: Australia Won't Meet the Hepatitis B Targets by 2030 Karen McCulloch, Who Collaborating Centre For Viral Hepatitis, The Doherty Institute, Victoria	2.30 - 2.45	Australia will need to increase testing to achieve hepatitis C elimination Nick Scott, Burnet Institute, Victoria
2.45 - 3.00	Maximising Adherence to Direct-Acting Antivirals Among Street-Based and Marginalised Clients: the Results of Daily Dosing Phillip Read, Kirketon Road Centre, New South Wales	2.45 - 3.00	Insights into HBV Prevalence and Vaccination in the Northern Territory: A Retrospective Longitudinal Study Ashleigh Qama, Who Collaborating Centre For Viral Hepatitis, Victoria	2.45 - 3.00	All stories matter in HCV elimination Kerrin Param, Sunshine Coast University Hospital, Queensland
3.00 - 3.15	Community-Based Hepatitis C Recruitment and Treatment for People Who Inject Drugs and Their Injecting Network is Feasible and Effective: The HCV Treatment and Prevention (Tap) Study Joseph Doyle, Burnet Institute, Melbourne, Victoria	3.00 - 3.15	Trends in Chronic Hepatitis B Prevalence in Australian Women by Country of Birth, 2000-2016 Wen-Qiang He, UNSW Sydney, New South Wales	3.00 - 3.15	Hepatitis C is a Rock n Roll Band: Taking DBS Testing To Bluesfest Maria McMahon, Hepatitis NSW, New South Wales

MONDAY 5 AUGUST 2019

3.15 - 3.30	The Meanings of Injecting in Sexualised Drug-Use Settings Among Gay Men Living With HIV Dean Murphy, UNSW Sydney, New South Wales	3.15 - 3.30	Addressing Viral Hepatitis in the Chinese, Filipino and Thai Communities Nafisa Yussf, Cancer Council Victoria	3.15 - 3.20	Integrating Hepatitis C Care with Mental Health and Alcohol and Other Drug Services Bradley Whitton, Alfred Health, Victoria
				3.20 - 3.25	Opportunities for Engaging Patients in Care Along the Hepatitis C Cascade of Care Alisa Pedrana, Burnet Institute, Melbourne, Australia
				3.25 - 3.30	Scaling Up Hepatitis C Treatment Among HIV Co-Infected Individuals Reduces Prevalence and New Infection: The Co-Ec Study Joseph Doyle, Burnet Institute, Victoria
3.30 - 3.35	Risk Behaviours Following Hepatitis C Treatment Among Gay and Bisexual Men Living With HIV in Melbourne, Australia Brendan Harney, Alfred Health & Burnet Institute, Victoria	3.30 - 3.35	Geographic Variation in CHB Prevalence in Aboriginal and Torres Strait Islander People Across Australia Jennifer Maclachlan, The Doherty Institute, Victoria	3.30 - 3.35	Low HCV Reinfection Incidence Following DAA Treatment Scale-Up in People Living With HIV in Australia Samira Hosseini Hooshyar, The Kirby Institute, UNSW Sydney, New South Wales
3.35 - 3.40	Injecting Culture Following Prison-Wide Hepatitis C Treatment Scale-Up: Negotiating Risk After Cure Lise Lafferty, Centre for Social Research in Health, UNSW Sydney, New South Wales	3.35 - 3.40	More Than Just 12 Kilometres: A Comparison of the Chinese and Vietnamese Communities Living With Hepatitis B in the Brisbane South PHN Marrianne Black, Ethnic Communities Council Of Queensland, Queensland	3.35 - 3.40	Hepatitis C Elimination in NSW by 2028 – Priming the System to Deliver Equity in NSW Annabelle Stevens, NSW Ministry of Health, New South Wales

Program: Monday

MONDAY 5 AUGUST 2019					
3.40 - 3.45	Hepatitis C Virus Reinfection Following Antiviral Treatment Among People Who Use or Inject Drugs: A Systematic Review and Meta-Analysis Behzad Hajari, UNSW Sydney, New South Wales	3.40 - 3.45	Understanding the Social and Cultural Experiences of People Affected by Hepatitis B William Mude, ARCSHS La Trobe University, Victoria	3.40 - 3.45	Distribution of Hepatitis C Treatment Related Knowledge Among People Who Inject Drugs: A Longitudinal Qualitative Study Stelliana Goutzamanis, Burnet Institute, Victoria
3.45 - 3.50	Expanding Testing and Treatment Programs for Hepatitis C Into Secondary Needle and Syringe Programs Stephen McNally, Pennington Institute, Victoria	3.45 - 3.50	Talking Testing: Best Practice in Hepatitis B and Hepatitis C Pre and Post Test Discussion Jen Johnson, Australian Research Centre In Sex Health and Society, La Trobe University, Victoria	3.45 - 3.50	Hepatitis C Treatment Strategy for Prisons: A Cost-Effectiveness Analysis Amy Jisoo Kwon, The Kirby Institute, New South Wales
3.50 - 3.55	Impact of Implementation of a Collaborative and Assertive HCV Focused Model of Care on Screening and Treatment Uptake, in a Metropolitan, Private Opioid Pharmacotherapy Clinic Sinead Sheils, Royal Prince Alfred Hospital, New South Wales	3.50 - 3.55	Filling the Gaps: Geographic Variations in the Hepatitis B and C Cascades of Care Jennifer MacLachlan, The Doherty Institute, Victoria	3.50 - 3.55	Improved Survival Following Hepatitis C-Related Hepatocellular Carcinoma Diagnosis in the Direct-Acting Antiviral Therapy Era in New South Wales, Australia Sichan He, University of New South Wales, New South Wales
3.55 - 4.00	Comparing Adherence to Once-Daily and Twice Daily DAA Therapy Among People With Recent Injection Drug Use or Current Opioid Substitution Therapy: The SIMPLIFY and D3FEAT Studies Evan Cunningham, Kirby Institute, UNSW Sydney, New South Wales	3.55 - 4.00	Barriers and Opportunities to Increase the Role of GPS in Hepatitis B Diagnosis, Treatment And Management: A Nationwide Survey of General Practitioners in Australia Yinzong Xiao, Burnet Institute, Victoria	3.55 - 4.00	The Challenge of Follow-Up: Hepatocellular Carcinoma Surveillance in Marginalized Patients with Cirrhosis Treated for HCV in a Low Threshold Primary Health Care Setting Phillip Read, Kirketon Road Centre, New South Wales
4.00 - 4.30	Afternoon Tea and Poster Viewing - Exhibition Area				

MONDAY 5 AUGUST 2019

4.30 - 6.30	Practice Workshop 1: Preventing liver cancer (HCC) in primary care: all you need to know	4.30 - 6.30	Practice Workshop 2: AOD Mental Health	4.30 - 6.30	Practice Workshop 3: Equity and Access: unlocking the keys to viral hepatitis elimination
	Room: Endeavour Room 2 Chairs: David Baker & Vanessa Towell		Room: Endeavour Room 1 Chairs: Sinead Sheils & Melanie Walker		Room: Endeavour Room 3 Chairs: Jack Wallace & Sandy Davidson
4.30 - 4.37	GP Forum Report Back Samuel Elliott, Riverside Family Medical Practice, SA	4.30 - 4.37	GP Forum Report Back Nada Andric, Homeless Healthcare, WA	4.30 - 4.37	GP Forum Report Back Belinda Greenwood-Smith, Coordinator, Centre for Disease Control, NT Health, NT
4.37 - 4.45	Nurse led model of care forum report-back Lynnaire Matthews, Haemophilia Foundation of New Zealand Inc	4.37 - 4.45	Nurse led model of care forum report-back Wendy Blanch, Sandon Integrated Health, Sydney	4.37 - 4.45	Nurse led model of care forum report-back Sally Watkinson, AHA, Melbourne
4.45 - 5.00	State of play in HCC screening, management and treatment outcomes Avik Majumdar, Royal Prince Alfred Hospital, Sydney	4.45 - 5.00	AOD Angela Corry, Peer Based Harm Reduction WA / AIVL President, Western Australia	4.45 - 5.00	Access, equity and living with hepatitis B Person with lived experience
5.00 - 5.15	Preventing HCC: global epidemiology and implications for care Benjamin Cowie, WHO Collaborating Centre for Viral Hepatitis, Melbourne	5.00 - 5.15	Mental Health Oliver Schubert, Northern Adelaide Local Health Network, SA	5.00 - 5.15	Key elements of services responding to cultural diversity Natali Smud, Multicultural HIV and Hepatitis Service (MHAHS), New South Wales

Program: Monday

MONDAY 5 AUGUST 2019					
5.15 - 5.30	Preventing HCC in primary care settings Nicole Allard, WHO Collaborating Centre For Viral Hepatitis, Melbourne	5.15 - 5.30	TOPIC inpatient study Gail Matthews, VHCRP, The Kirby Institute, UNSW, New South Wales	5.15 - 5.30	Hep B PAST – concepts, progress and partnerships Kelly Hosking, Hepatitis B Program Manager, Top End Health Service, Northern Territory Government, PhD Candidate Menzies School of Health Research, Northern Territory Linda Bunn, Aboriginal Health Coordinator, Top End Health Service, Northern Territory Government
5.30 - 6.30	Panel Discussion Nicole Allard, Christopher An, David Baker, Anne Balcomb, Benjamin Cowie, Dianne How-Chow, Avik Majumdar, Phillip Read, Nafisa Yussif	5.30 - 6.30	Panel Discussion Angela Corry, Oliver Schubert, Heidi Coupland, Gail Matthews	5.30 - 5.45	Overview of inequity, their practical impact and how they can be addressed Chris Cunningham, Te Pūmanawa Hauora Massey University, Wellington, New Zealand
				5.45 - 6.30	Panel Discussion Kelly Hosking, Chris Cunningham, Person with lived experience, Natali Smud, Linda Bunn
6.30 - 9.30	Conference Networking Dinner Including presentations on: <ul style="list-style-type: none"> • Presentation of the 2019 Prize for the National Competition for Excellence in Hepatitis C Health Promotion • Australia's progress towards hepatitis C elimination: Annual Report 2019 (launched by the Burnet Institute and Kirby Institute) 				

Program: Tuesday

TUESDAY 6 AUGUST 2019	
7.00	Registration
7.30 - 8.30	Meet the Elimination Experts Networking Breakfast Room: Endeavour Ballroom 2 Chair: Nikitah Habraken Panellists: Greg Dore, Saeed Hamid, Sharon Hutchinson, Giten Khwairakpam, Dee Lee, Rosie Gilliver, Jason Grebely
9.00 - 10.30	Plenary 3: Engaging people in testing and care Room: Endeavour Ballroom Chairs: Helen Tyrell & Anne Balcome
9.00 - 9.20	Finding the Missing Millions: Patients' Lived Experiences Informing Screening & Care Efforts Su Wang, Center for Asian Health at Saint Barnabas Medical Center, United States of America
9.20 - 9.40	Community mobilisation - The way ahead Stuart Loveday, Hepatitis NSW, Sydney, Australia
9.40 - 10.00	Married at first site? Engagement and the challenge of eliminating hepatitis C in Australia Alexander Thompson, St Vincent's Hospital, Melbourne, Australia
10.00 - 10.30	Panel Discussion
10.30 - 10.35	Launch of the Annual Report of Trends in Behaviour Viral Hepatitis, Centre for Social Research in Health UNSW Joanne Bryant, Centre for Social Research In Health UNSW, Sydney, Australia
10.30 - 11.00	Morning Tea and Poster Viewing - Exhibition Area
11.00 - 12.30	Plenary 4: Measuring our progress and success Room: Endeavour Ballroom Chairs: Alex Thompson & Lauren Bradley
11.00 - 11.20	Progress on Hepatitis C elimination in Scotland Sharon Hutchinson, Glasgow Caledonian University, Scotland
11.20 - 11.40	Hepatitis C elimination in NSW - where are we now? Kerry Chant, New South Wales Health, Sydney, Australia
11.40 - 12.00	Progress towards hepatitis C elimination in Australia - A National Update Alisa Pedrana, Burnet Institute, Melbourne, Australia
12.00 - 12.30	Panel Discussion
12.30 - 1.30	Lunch and Poster Viewing - Exhibition Area

Program: Tuesday

TUESDAY 6 AUGUST 2019

12.45 - 1.15	Poster Tour 2 Room: Exhibition Area Chair: Jack Wallace	12.45 - 1.15	Poster Tour 3 Room: Exhibition Area Chair: Melanie Walker
12.45 - 12.50	Do Speak the Same Language Good Enough? - Lesson Learnt from Working with the Chinese Community Sha Liu, Ethnic Communities Council of Queensland	12.45 - 12.50	Accessing Hidden Populations: An Extended Outreach Service of the Kirketon Road Centre Rosie Gilliver, Kirketon Road Centre, New South Wales
12.50 - 12.55	From Partnership to Leadership: Victorian Chinese Community Mobilise to Eliminate Hepatitis B Aurora Tang, Hepatitis Victoria	12.50 - 12.55	Epidemiology of Chronic Hepatitis B and C In Victoria: Insights and Impacts from Enhanced Surveillance Jennifer MacLachlan, The Doherty Institute, Victoria
12.55 - 1.00	Let's Stick Together to Close the Gap Sandy Davidson, Hepatitis NSW, New South Wales	12.55 - 1.00	A Cost-Effectiveness Analysis of Primary Versus Hospital-Based Specialist Care for Direct Acting Antiviral Hepatitis C Treatment Anna Palmer, Burnet Institute, Victoria
1.00 - 1.05	Supporting People Living with Chronic Hepatitis b (CHB) in the Myanmar Community Evelyn Pe, Ethnic Communities Council of Queensland	1.00 - 1.05	High Efficacy of Direct-Acting Antiviral Therapy for Chronic HCV In An Australian Real-World Cohort: The Reach-C Study Jasmine Yee, The Kirby Institute, UNSW Sydney, New South Wales
1.05 - 1.10	Multiple Approaches to Awareness on Viral Hepatitis B and the Availability of Free Vaccine Among the Cambodian Community in South East Melbourne Sambath My, Hepatitis Victoria	1.05 - 1.10	A Combined Treatment and Prevention Approach is Vital in Eliminating Hepatitis C Virus in Australian Prisons: A Modelling Study Neil Arvin Bretana, UNSW Sydney, New South Wales
1.10 - 1.15	Challenging Cultural Assumptions Beyond Viral Hepatitis Elimination: The Diversity Hub Experience Sonam Paljor, Diversity Programs and Strategy Hub, Multicultural HIV and Hepatitis Service, New South Wales	1.10 - 1.15	A Global Investment Framework for Hepatitis C Elimination Alisa Pedrana, Burnet Institute, Victoria

TUESDAY 6 AUGUST 2019

1.30 - 4.30 Plenary 5: Re-orientating health services for priority population access

Room: Endeavour Ballroom

Chairs: Barbara Luisi & Vanessa Towell

1.30 - 1.45 **Epidemiology of viral hepatitis and responses in Australasia and our region**

Benjamin Cowie, WHO Collaborating Centre for Viral Hepatitis, Melbourne, Australia

1.45 - 2.00 **How stigma can undermine the viral hepatitis elimination strategy by 2030 in WPRO region**

Dee Lee, Inno Community Development Organisation, China

2.00 - 2.15 **Aboriginal and Torres Strait Islander researcher & community perspective**

James Ward, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia

2.15 - 2.30 **Viral Hepatitis and Māori Health**

Chris Cunningham, Te Pūmanawa Hauora Massey University, Wellington, New Zealand

2.30 - 3.00 **Panel Discussion**

3.00 - 3.30 Afternoon Tea and Poster Viewing - Exhibition Area

3.30 - 4.30 **Closing Plenary: Challenges and priorities ahead**

Room: Endeavour Ballroom

Chairs: Greg Dore & Jacqui Richmond

3.30 - 3.45 **Levinia Crooks Emerging Leaders Award Presentation**

3.45 - 4.25 **Panel Discussion - Steps for the Future where will we be in 2021**

Panelists: Lisa Carter, Greg Dore, Saeed Hamid, Sharon Hutchinson, Stuart Loveday, Su Wang

4.25 - 4.30 **Thank you and farewell**

Alexis Apostolellis, CEO, ASHM

4.30 Conference concludes

Poster Listing

#	PRESENTER	TITLE OF PRESENTATION
1	SANDY DAVIDSON	Addressing Stigma Associated with Hepatitis B Among Chinese and Korean Australians: Family Health and Cancer Prevention
2	SANDY DAVIDSON	Let's Stick Together to Close the Gap
3	SHA LIU	Do Speak the Same Language Good Enough? – Lesson Learnt from Working with the Chinese Community
4	SAMBATH MY	Multiple Approaches to Awareness on Viral Hepatitis B and the Availability of Free Vaccine Among the Cambodian Community in South East Melbourne
5	SONAM PALJOR	Challenging Cultural Assumptions Beyond Viral Hepatitis Elimination: The Diversity Hub Experience
6	EVELYN PE	Supporting People Living with Chronic Hepatitis B (CHB) in the Myanmar Community
7	AURORA TANG	From Partnership to Leadership: Victorian Chinese Community Mobilise to Eliminate Hepatitis B
8	NICOLE ALLARD	Evaluating the Coverage of Hepatitis B Workforce Development in Primary Care
9	TANYA APPEGATE	Evaluation of HCV RNA Testing from Finger-Stick Capillary Dried Blood Spot and Venepuncture-Collected Samples: A Cohort Study
10	DAVID BAKER	Never Fear- Polar is Here; A Nationally Available Tool for Chronic Hepatitis B Management in General Practice
11	SOFIA BARTLETT	Hepatitis C Virus Treatment Uptake Differs According to Recency of Opioid Agonist Therapy Among People Who Inject Drugs with Chronic Hepatitis C Infection
12	MARIAN BLOOMFIELD	Dried Blood Spot for HIV and HCV – Testing Priority Population Groups in the NSW Custodial Setting
13	SAMANTHA BOLTON	Hepatitis C Treatment in Prison: A Forum for Queensland
14	REBECCA BOWMAN	** WITHDRAWN ** Resistance, Reinfection or Relapse: A Case Study
15	LAUREN BRADLEY	Custodial Settings: The Missing Link to Hepatitis C Elimination
16	SUSAN CAMPFIELD	Community-Based Model of Care for Hepatitis C Treatment
17	MARILOU CAPATI	Epidemiology of Chronic Hepatitis B in a Bulk-Billing GP Clinic in Darwin
18	HEIDI COUPLAND	"I'll Have Hep C Treatment Eventually": Shedding Light on What it Takes to Increase Hepatitis C Treatment Uptake When Clients Have Other Priorities
19	EVAN CUNNINGHAM	Reinfection Following Successful HCV DAA Therapy Among People with Recent Injecting Drug Use or Current Opioid Substitution Therapy
20	OLIVIA DAWSON	Hepatitis C Education for NSP Frontline Workers: Preliminary Evaluation Findings from a National Capacity Strengthening Program
21	JULIE-ANNE DOWNIE	Hep C Project Inreach 'Same Same But Different Setting'
22	N/A	N/A

#	PRESENTER	TITLE OF PRESENTATION
23	MARLEY EASTERBROOK	Open-Access HBV Research Protocol Database
24	ANNETTE FRASER	The One Phone Call at a Time Approach to Eliminating Hepatitis C in the Western Australian Community
25	LOUISE GEDDES	Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection
26	JASON GREBELY	HCV Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Patients on Opioid Agonist Therapy: Co-Star Part B
27	BRENDAN HARNEY	A Nurse-Led, Community Based Model of Hepatitis C Care in Melbourne, Australia; 2017-2018
28	BRENDAN HARNEY	Hepatitis B Immunity and Susceptibility Among People Living with HIV and Hepatitis C Co-Infection in Melbourne, Australia
29	SICHAN HE	Effectiveness of Direct-Acting Antiviral Treatment for Hepatitis C Among People with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
30	JO HOLDEN	Dried Blood Spot (DBS) Testing Pilot
31	DIANNE HOW CHOW	Hepatitis C Specialist Nurses Use Notification Data to Enhance Engagement with and Education of General Practitioners in South Eastern Sydney
32	DIANNE HOW CHOW	ICHAT. Evaluation of an Innovative Nurse Led Primary Health Model of Care for Patients with Hepatitis C in Inner City Sydney
33	BEHZAD HAJARIZADEH	Uptake of Hepatitis C Direct-Acting Antiviral Treatment Among Individuals with HIV Co-Infection in Australia.
34	HAYDEN JOSE	Improved Hepatitis B Testing and Management Among GPS that Have Completed S100 Hepatitis B Community Prescriber Program Training
35	SHELLEY KERR	Removing Barriers: An Online Learning Module for Nurses to Eliminate Stigma and Discrimination Towards People Living with Blood-Borne Viruses
36	CHLOE LAYTON	Supporting Primary Care Clinics to Prioritise Hepatitis C Testing and Treatment - the EC Nurse-Led Model.
37	KYLE LEADBEATER	The Value of a Peer and Clinical Partnership to Facilitate Hepatitis C Healthcare Access in Priority Settings
38	CAROLINE LEE	Adherence and Virological Outcomes of Hepatitis B Antiviral Therapy Amongst Indigenous and Non-Indigenous Patients in the Remote Top End, Northern Territory
39	ALISON MARSHALL	Barriers and Facilitators to Engaging in HCV Management and DAA Therapy Among General Practitioners and Drug and Alcohol Specialists - The Practitioner Experience
40	COLETTE MCGRATH	Hepatitis in Prisons Elimination (HIPE) Program, Phase One: Outcomes and Lessons Learned
41	KERRIE MCKENZIE	Opportunistic Engagement Through NSPS in a Community Setting

Poster Listing

#	PRESENTER	TITLE OF PRESENTATION
42	WINNIE NGUYEN	Enhancing HCV Treatment in the Transition Space: Hepatitis C Probation and Parole Pilot in South East Queensland
43	MIM O'FLYNN	Towards Cure on the Inside
44	JOSS O'LOAN	HCV in the Australian Primary Care Setting: Real World Effectiveness of 12 Weeks of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C
45	JULIE PAGE	Indoctrination – Upskilling Doctors in Real World Settings
46	ANUP JOHN PEREIRA	A Leap in the Right Direction- Debunking Myths, Solidifying Engagement and Transforming Health Attitudes Within Canberra's Multicultural Settings
47	MEG PERRIER	Hepatitis B Adult Migrant Education; Moving Towards a Sustainable Space
48	JEFFREY POST	Opportunistic Assessment and Treatment of People with Hepatitis C Virus Infection Admitted to Hospital for Other Reasons: A Prospective Cohort Study
49	JEFFREY POST	Safety, Effectiveness and Potential Contribution to Hepatitis C Virus (HCV) Elimination of a Prison-Based Nurse-Led HCV Treatment Program in NSW, Australia
50	DARREN RUSSELL	So Your Prison is Hep C Free – Now What?
51	DARREN RUSSELL	On the Road to Making 'Cairns Hep C Free by 2020' - Are We There Yet?
52	N/A	N/A
53	NICK SCOTT	A Global Investment Case for Hepatitis C
54	LINDA SELVEY	** WITHDRAWN ** Personal, Provider and System Level Barriers and Enablers for HCV DAA Treatment in General Practice Settings
55	CHRISTINE SELVEY	Use of Routine Hepatitis Notification Data to Support DAA Treatment Uptake in New South Wales
56	SARAH SMITH	Hepatitis B Pop-Up Screening at UNSW - Was it all Worth it?
57	SARAH SMITH	Hepatitis B Community Outreach Testing – Success Through Collaboration
58	SARAH SMITH	Turning Outward: Using Community Conversations with People Who Inject Drugs in Southern Sydney to Understand the Factors Influencing Their Health and Wellbeing
59	AZRIEL TAN	Sub-Optimal Patterns of HCV Testing in Hospitalised People Who Inject Drugs: A Missed Opportunity?
60	ALEX THOMPSON	Global Real World Evidence of Sofosbuvir/Velpatasvir as a Simple, Effective Regimen for the Treatment of Chronic Hepatitis C Patients: Integrated Analysis of 12 Clinical Practice Cohorts
61	DANIKA TREMAIN	Dried Blood Spot Testing in Drug and Alcohol Clinical Services: A Pilot Study
62	HEATHER VALERIO	Uptake of Testing, Linkage to Care, and Treatment for Hepatitis C Infection Among People Who Inject Drugs in Australia: The Ethos Engage Study
63	SAMANTHA WHITE	Be Liver Smart Project

#	PRESENTER	TITLE OF PRESENTATION
64	YINZONG XIAO	Systematic Review of Methods for the Surveillance of Hepatitis B Virus in Low Prevalence Countries, 2017
65	MATTHEW YOUNG	The Kombi Clinic – It's the End of the Road for Hepatitis C
66	SAHAR BAJIS	Hepatitis C Virus Testing, Liver Disease Assessment and Treatment Uptake Among People Who Inject Drugs Pre- and Post-Universal Access to Direct-Acting Antiviral Treatment in Australia: The Liverlife Study
67	ANNE BALCOMB	Australian Rural Primary Care Led Viral Hepatitis Clinic - Outcome Data from 3 Years of Direct Acting Antiviral Agents (DAA's).
68	BRIDGET DRAPER	Community-Based Point-Of-Care Testing and Treatment for People Who Inject Drugs and General Population in Myanmar
69	INGRID FRANCIS	Collaborative Approach to the Management of Hepatitis C at Numinbah Queensland Correctional Facility
70	PETA GAVA	Nothing About us Without us: The Role of Peer Educators in HCV Testing and Treatment Uptake
71	JAKE WILLIAMS	Universal Blood-Borne Virus Screening in Patients with Severe Mental Illness Managed in an Outpatient Clozapine Clinic: Uptake and Prevalence
72	ALISA PEDRANA	Hepatitis C Antibody Testing Trend Pre and Post Universal Access to Direct Acting Antivirals in Australia: Segmented Regression of Primary Care Clinic Data
73	ALISA PEDRANA	A Global Investment Framework for Hepatitis C Elimination
74	ALISA PEDRANA	Knowledge of Hepatitis C Testing and Treatment Guidelines Among People at Risk of, or Living with, Hepatitis C
75	ALISA PEDRANA	Tailoring Hepatitis C Health Promotion for People Who Inject Drugs
76	NEIL ARVIN BRETANA	A Combined Treatment and Prevention Approach is Vital in Eliminating Hepatitis C Virus in Australian Prisons: A Modelling Study
77	JENNIFER MACLACHLAN	Epidemiology of Chronic Hepatitis B and C in Victoria: Insights and Impacts from Enhanced Surveillance
78	ANNA PALMER	A Cost-Effectiveness Analysis of Primary Versus Hospital-Based Specialist Care for Direct Acting Antiviral Hepatitis C Treatment
79	JASMINE YEE	High Efficacy of Direct-Acting Antiviral Therapy for Chronic HCV in an Australian Real-World Cohort: The Reach-C Study
80	ROSIE GILLIVER	Accessing Hidden Populations: An Extended Outreach Service of the Kirketon Road Centre
81	PHILLIP READ	Partnering with Consumers: The Development of a Primary Health Care Hepatitis C Treatment Model Within a Peer-Based Needle and Syringe Program
82	PHILLIP READ	When Treatment Access Does Not Equal Treatment Initiation: An Analysis of Clients Who Do Not Initiate Direct Acting Antivirals

Notes

[illegible]

[illegible]

[illegible]

[illegible]

NEED A REFRESHER? LEARN WITH US.



ashm

**Developing a sustainable HIV, viral
hepatitis and sexual health workforce**

ASHM provides world-class, award-winning clinical education to GPs, specialists, nurses and other health workers.

Our free online modules cover a wide range of topics in HIV, viral hepatitis and sexual health, and many are eligible for CPD points.

Register online today at lms.ashm.org.au